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ABSTRACT
We have examined the chicken Very Low Density
Apolipoprotein 11 (apoVLDL 11) gene locus in transgenic
mice. A DNA fragment composed of the transcribed
region, 16 kb of 5' flanking and 400 bp of 3' flanking
sequences contained all the information sufficient for
estrogen-inducible, liver-specific expression of the
apoVLDL 11 gene. The far-upstream region contains a
Negative Regulating Element coinciding with a DNasel-
hypersensitive site at -11 kb. In transgenic mice, the
NRE at -11 kb is used for downregulating the ex-
pression to a lower maximum level. The NRE might be
used for modulating apoVLDL 11 gene expression, and
may be involved in the rapid shut-down of the
expression after hormone removal.
INTRODUCTION
The ability for stimulus-induced tissue-specific gene expression
during development and differentiation in higher organisms is
preprogrammed. In this way, different cells can use the same
stimulus for different expression programs. The stimulus can have
an environmental cause like infection, starvation or stress.
Alternatively, it can be a molecule involved in intercellular
signaling, for example a hormone (1). The chicken apoVLDL
II gene provides an example of a gene which is expressed tissue-
specifically and is strictly dependent on a hormone (2). In this
case, the liver is the expressing tissue and estradiol is the inducing
hormone. In other tissues, estradiol stimulates the transcription
of different genes, for example in chicken oviduct the lysozyme
gene is stimulated several-fold (3). The regulation of the
expression of these genes requires the action of trans-acting
transcription factors and cis-acting DNA elements, like
promoters, silencers and enhancers (1,4,5).
Control regions conferring liver-specific expression in
transgenic mice have been shown for example with the human
al-antitrypsin (6), al-glycoprotein (7) and apoCI VLDL (8)
genes, and the mouse abumin (9), oa-fetoprotein (10),
angiotensinogen (11) and transthyretin (12) genes. The expression
of a transgene is often influenced by its chromosomal position,
resulting in highly variable expression that is not related to the
transgene copy number. Some examples are known in which the
transgene is expressed in a position-independent, copy-number
dependent manner (13-16). The information for position-
independent, copy-number dependent expression is provided by
so-called Locus Control Regions.
We have shown previously that the induction of the apoVLDL
II gene in liver is marked by the appearance of DNasel-
hypersensitive sites (HSS) in the transcribed and flanking regions
(17; see Figure 1). One set of DNasel HSS is present in the
sequence immediately 5' flanking to the gene. Genomic foot-
printing experiments demonstrated the tissue-specific and
estrogen-dependent interaction of transcription factors with the
300-bp promoter region of the gene (18,19). The function of this
region has been examined by transient gene transfer experiments
(20,2 1). The region contains two estrogen response elements
(EREs). In vitro DNasel footprinting and band-shift analysis has
yielded a detailed picture of the protein binding sites in the
promoter region. In addition to the estrogen receptor, proteins
binding to these sites (18,19) are the ubiquitous COUP-
transcription factor (22) and the liver-enriched transcription
factors C/EBP (23), DBP (24) and LF-A1 (25). In addition to
the estrogen-inducible sites, constitutive, liver-specific HSS have
been mapped, notably at 1.7 kb and 11 kb in front of the gene
(17 and unpublished data).
In the current studies with transgenic mice, we attempt to
delineate the apoVLDL II gene domain. A DNA construct
covering the transcribed region and 16 kb of 5' flanking DNA
exihibited liver-specific and estrogen-inducible expression. Within
this gene construct the far-upstream region contains information
for silencing transcription in non-liver tissues. A DNA fragment
covering a DNaseI hypersensitive site at -11 kb could be
operationally defined as a Negative Regulating Element (NRE).
This NRE may have an important function in the modulation of
the apoVLDL II gene expression, specifically in preventing
uncontrolled expression which would result in hyper-
triglyceridemia (8).
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MATERIALS AND METHODS
Transgenic mice
Transgenic mice were generated as described (26-28).
Fragments for micro-injection into the pronuclei of ferilized eggs
from CBAxC57BL/10 mice were purified from plasmid
sequences by gel electrophoresis, glass beads and an Elutip-d
column. Southern blot analysis of EcoRI digested tail DNA was
used to identify transgenic mice. Three-weeks-old mice were
estrogen-stimulated for 2 days by daily s.c. injections of 50 1l
0.4 mg/ml 17(-estradiol in 1,2-propylene glycol unless otherwise
indicated.
Constructs
A 20-kb SailI fragment containing the complete 2.9-kb apoVLDL
gene, 400 bp of 3' flanking and 16 kb of 5' flanking DNA
was purified from a lambda EMBL3 VLDL clone (Philipsen,
S., Meinsma, D. and AB, G., unpublished) and cloned into the
SalI site of pUC18 forming clone 20VLDLpUC18. This clone
was cut with BamHI and religated, thereby deleting the -16 kb
to -5 kb region and forming clone 9VLDLpUC18. The 9-kb
BamHI/SalI apoVLDL II fragment from 9VLDLpUC18 was
subcloned in the BamHI/SalI sites of the Bluescript vector,
forming 9VLDLpBlue. A 2-kb BamHI/EcoRl 5' fragment from
- 12.5 kb to -10.5 kb was blunted and cloned in the correct
orientation into the blunted BamnH site of9VLDLpBlue, forming
1 lVLDLpBlue.
A 20-kb SalI fragment from 20VLDLpUC 18, a blunted 9-kb
BanHI/SalI fragment from 9VLDLpUC18 and a 11-kb Notd/SalI
fragment from 1 IVLDLpBlue were used to generate transgenic
mice.
DNA analysis
DNA from different tissues was digested with EcoRI, TaqI or
BamHI, Southern blotted (29) onto nylon or nitrocellulose
membranes and probed with apoVLDL and Thy-i specific
probes. The probes used were a 674-bp BstEIH/EcoRI fragment
from apoVLDL II intron A, a 1. 1-kb EcoRI/BamHI fragment
from the apoVLDL 5' flanking region, and a 1413-bp ApaI
fragment from Thy-I exon 4. Copy-numbers were estimated on
a Phospho-imager using Thy-i as an internal control.
RNA analysis
Total RNA was isolated from tissues homogenized in 3 M LiCl
6 M Urea (30).
Northern blotting was performed as described by Krumlauf
(31). Northern blots were hybridized with a 506-bp apoVLDL
II cDNA probe excised from pGEMVLDL-18A with Sacd
(Wijnholds, unpublished data). The blot was rehybridized with
a 460-bp Eco-RI/Tthllh mouse histone H4 probe as an internal
control to correct for loading differences.
SI nuclease protection analysis was carried out as described
by Kollias et al. (28). Probes used were a 3' end-labeled 670-bp
SpeI/SailI apoVLDL 11-fragment from 9VLDL-pUC18 and a
430-bp ,B-actin XhoI/AvaI-fragment from pHF,BA-1 (32). Total
RNA (5 ,ug) and labeled DNA probes (10-30 ng) were co-
precipitated, resuspended in 20 ,ul S,-hybridization buffer (40
mM PIPES, pH 6.4; 400 mM NaCl, 1 mM EDTA, 80%
formamide) and incubated at 51°C for 16 h. Samples were
digested with 200 units of S, nuclease (Boehringer Mannheim)
at 25°C for 2 h after adding 200 A1 of SQ digestion buffer (280
mM NaCl, 30 mM NaAc, pH 4.8, 2 mM ZnSO4). The reaction
was stopped by adding 20 1l 50 mM EDTA, 1% SDS and 10
jgg tRNA. After phenol-chloroform extraction, ethanol
precipitation, and resuspension in 5 IL S1 loading buffer (7 M
urea, 5 mM Tris-borate, 1 mM EDTA, 0.1% xylenecyanol,
0.1% bromophenolblue) the samples were analyzed on a 5%
polyacrylamide, 7 M urea sequencing gel.
Primer extension analysis was perfonned using a 26-nucleotide
apoVLDL 11 pimer, 5'-CTGTCCTGCTTTCTCTCTCCC-
AGGCT-3', from exon 1. Total liver RNA (5 itg) and 105cpm[a-32P]-labelled primer (108 cpm/tg) were co-precipitated,
resuspended in 8 1l H20, and 2 11 annealing buffer (1.25 M
KCl, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA) was added. The
samples were incubated for 1 hr at 65°C, cooled on ice and
supplemented with 23 yl extension mix (20 mM Tris-HCl, pH
8.3, 10 mM MgCl2, 10 /Ag/ml actinomycin D, 5 mM DTT and
1 mM dNTP's) and 1 ll 10 U/4l AMV reverse transcriptase.
The reaction was incubated for 1 h at 42°C, stopped by the
addition of phenol/chloroform and extracted in the presence of
10 yig carrier tRNA. The samples were ethanol precipitated,
resuspended in 5 il of SI loading buffer and analyzed on a 8%
sequencing gel.
DNAaseI HSS mapping
Nuclei were isolated according to Gorski et al. (34) and
resuspended at a DNA concentration of 1 mg/ml in 15 mM Tris
pH 7.5, 60 mM KCl, 15 mM NaCl, 0.2 mM EDTA, 0.2 mM
EGTA, 0.15 mM spermine, 0.5 mM spermidine. Incubation of
the nuclei was according to Philipsen et al (36). DNAaseI
(Worthington) was added to concentrations of 1-8 Ag/ml, and
the reaction was started by the addition of MgCl2 to 10 mM and
CalCl2 to 1 mM final concentration. The reaction was allowed
to proceed for 5 min on ice, and stopped by the addition of 1
vol 50 mM EDTA, 1% SDS. DNA was isolated, digested with
appropriate restriction enzymes and analyzed by Southern
blotting.
RESULTS
Transgenic mice containing the apoVLDL II locus
Transgenic mice containing the chicken apoVLDL 11 gene locus
were generated. The DNA fragments used for micro-injection
contained the transcribed region, 400 bp of 3' flanking region
and either 16 kb (construct 20V) or 5 kb (construct 9V) of 5'
flanking DNA (Figure 1). An additional DNA construct
(construct 1 1V) was used in which the BamHl/EcoRl fragment
between coordinates -12.5 to -10.5, covering the DNaseI-
hypersensitive site at -11 kb, was cloned in front of construct
9V. The hypersensitive site may represents a site ofprotein-DNA
interaction involved in the regulation of the apoVLDL 11 gene.
Newborn mice were screened by Southern blotting of EcoRI-
digested tail DNA, using an apoVLDL 11-specific probe. Three
founder transgenic mice (20V17, 20V20 and 20V22) were
obtained with construct 20V, two (9V7 and 9V8) with construct
9V and five (1lV5, 1 1V6, 1 V9, 1lV 13, 1 1V15) with construct
11V. Mice 20V20 and 20V22 were used to generate F1 offspring.
For further analysis of the founder mice, EcoRI-digested DNA
from at least four tissues (liver, brain, kidney and lung) was
hybridized with a chicken apoVLDL II probe and a Thy-I probe
as a loading control. Only mouse 1 IV15 showed a different ratio
in the transgene versus Thy-I control signal in the various tissues
and this is therefore the only mosaic animal in these experiments.
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Figure 1. Map of the chicken apoVLDL II gene locus. The upper line shows the apoVLDL-II(apoII) locus. The bold and thin arrows indicate strong and weak
DNAaseI hypersensitive sites, respectively, in chicken. The transcribed region is indicated as a bold block. The coordinates are given in kb relative to the cap site.
The next three lines show the BamHI and EcoRI restriction maps and the apoVLDL II probes (1, 2, 3 and 4) used for Southern blotting and SI-nuclease analysis.
The length of the internal restriction fragments is indicated in kb. B, BamHI; Bs, BstEII; E, EcoRI; M, MboI; N, Notl; S, SailI; Sp, SpeI; T, TaqI. The constructs
20V, 9V and lIV used to generate transgenic mice are indicated on the lower four lines.
Table I. Expression levels of chicken apoVLDLII mRNA in transgenic mice
Mouse Copy Sex Apoll mRNA (3-actin mRNA ApoIII/(-actin mRNA
number cpma cpm ratio
20V17 14 F 122,259 23,059 5.30
20V20a 6 F 19,607 14,783 1.33
20V20b 6 F 52,455 20,632 2.54
20V20b(-) 6 F 0 10,368 0
20V22 2 M 28,270 9,477 2.98
20V22(-) 2 M 7,914 11,382 0.70
1 lV5 8 F 96,295 20,898 4.61
1lV6 15 M 107,771 27,670 3.89
1 lV9 4 F 100,050 25,878 3.87
1 IV13 27 F 84,616 54,317 1.56
llIV15 20b F 12,177 6,714 1.81
9V7 7 F 84,625 5.631 15.03
9V8 3 M 66,138 4,570 14.47
aCorrected for the signal (1,466 cpm) in non transgenic mice.
bMouse lIV15 is mosaic.
The integrity of the integrated DNA was checked by Southern
blotting; no rearrangements had occurred during chromosomal
integration (data not shown). The constructs were inserted as
multimers in a head-to-tail configuration into single locations of
the mouse genome. The sites of chromosomal integration differed
between the mice, as could also be concluded from restriction
analysis. VLDL copy-numbers estimated with a Phosphor-Imager
using the Thy-l single-copy gene as a reference varied from 2
to 27 and are compiled in Table I.
The chicken apoVLDL II mRNA is correctly processed in the
transgenic mouse liver
To establish whether the correct transcription initiation sites of
the chicken apoVLDL II gene are used in mouse, total RNA from
the livers of estrogen-treated transgenic mice was analyzed by
primer extension. Chicken liver RNAs from adult females and
estrogen-treated males were used as positive controls. Using an
exon-1 specific primer, three different extension products
(Figure 2) were found corresponding to the major start site
(nominated +1) and two minor start sites (-11 and + 7)
described earlier (36). The start sites used in chicken (lanes 2
and 3) are also used in the transgenic mice (lanes 1 and 5-7).
To investigate whether the proper polyadenylation site is used
in the mouse liver, we performed S1 nuclease protection
experiments. The results show that the chicken apoVLDL II
transcript has the correct 3' terminus in transgenic mice
(Figure 3). Furthermore, the mature transcripts in transgenic mice
and chicken appear to be of the same length on Northern blots
(Figure 4A), indicating that the apoVLDL II mRNA is correctly
spliced in transgenic mice. Apparently, the avian signals for
initation, poly-A addition and processing are faihfullly recognized
by mammals.
Liver-specifi'c and estrogen-inducible apoVLDL H gene
expression in transgenic mice
Quantification of the apoVLDL II gene expression in the livers
of transgenic mice by S1 nuclease protection experiments
(Figure 3) showed that construct 20V is expressed to similar
levels as the mouse 3-actin gene, which means that the transgene
is expressed at high level. Compared to chicken liver where the
apoVLDL II transcript forms about 10 % of the total mRNA (2)
apoVLDL II expression in mouse liver is 30-fold lower.
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Figure 2. Primer extension analysis of transcription start site. A 26-nt apoVLDL
II primer was annealed to total liver RNA, extended with reverse transcriptase
and displayed by electrophoresis. Reactions contained 15 /tg total RNA of the
transgenic mouse 20V17 (lane 1), or 5 ,ug total RNA from a laying hen (lane
2), an estrogen-treated rooster Oane 3), a hormone-naive rooster (lane 4) and
the transgenic mice 20V17 (lane 5), 9V7 Oane 6) and 9V8 (lane 7). A sequence
ladder (G, A, T, C) generated with the same primer on an apoVLDL II DNA
template was run in parallel. The positions of the three sets of cap sites in chicken
and transgenic mice correlating with the length of the extended fragments are
indicated.
The expression of the chicken apoVLDL II gene in mouse liver
proved to be dependent on estrogen as is the case in the chicken
liver. This became clear when comparing a three-week-old, six-
gene-copy transgenic mouse, 2OV20b (Figure 3, lane 8), that had
been injected with estradiol, to its age-matched hormone-naive
sister 20V20b(-) (lane 9) in a S1 nuclease protection experiment.
At the age of 3 weeks, female mice are not yet in the estrus-
cycle (37). The hormone enhanced the level of apoVLDL
transcripts at least 500-fold. Similar results were obtained with
male mice. The estrogen-dependent expression was also evident
from the Northern analysis (Figure 4B). Whereas the estrogen-
treated mouse liver RNA already gave a clear band on a Northern
blot after a three-hour exposure, the non-stimulated mouse yielded
only a faint signal of the correct size after one-week exposure
(data not shown). When the two-gene-copy transgenic male
mouse 20V22 was compared with its hormone-naive brother
20V22(-), a four-fold induction was found (Figure 3, lanes 10
and 11). This much lower induction-factor is due to the relatively
high expression level of the transgene in the hormone-naive
mouse, which is probably caused by positive chromosomal
position effects. The gene may have been integrated into a
chromatin locus with an open conformation, allowing a substantial
level of basal transcription. Steroid receptors are believed to act
in two different ways, either by a de-repression mechanism
involving chromatin opening or by a direct activation/enhancing
mechanism accelerating the formation of the transcription
complex at the promoter. The four-fold induction by estrogen
Fgure 3. Quantitation ofapoVLDL II mRNA levels in transgenic mice. Nuclease
protection analysis of total liver RNA and a mixture of 3' labelled apoVLDL
II probe 3 (see Fig. 1) and (3-actin probes (see Materials and Methods) is shown.
The protected 257-nt 3' apoVLDL II fragment (apoll) and the 100-nt ,B-actin
(8-A) fragment as well as the input DNA bands (ip) along with the size (nt) of
marker DNA fragments are indicated. Lanes 1-5 contained control SI-reactions
of: 3 xthe standard amount of transgenic mouse (9V8) liver RNA (lane 1); 5
ytg chicken liver RNA from a mature hen (CLH; lane 2) or mature rooster (CLR;
lane 3,4), 5 ,ug RNA from a non-transgenic mouse (NTG, lane 5). Lanes 6- 23
contained SI-reactions in the presence of 5 ug RNA from transgenic mice with
VLDL constructs 20V (lanes 6-11), I1V (lanes 12-16) and 9V (lane 17-18).
All experimental animals were treated with estrogen except for those indicated
with (-).
of the two-copy transgene may represent the activator/enhancer
activity of the estrogen receptor. (18,19,21,38,39).
When total RNA from different transgenic tissues (ovary plus
oviduct, uterus, testis, speen, kidney, brain, thymus, heart, lung
and small intestine) were examined (Figure 4A and data not
shown), no transcripts were detectable even after one week of
exposure. In summary, the apoVLDL II transgene expression
is liver specific, estrogen-inducible, and occurs at high level.
Sequences required to confine expression to the liver
In all the apoVLDL II transgenic mice analyzed, the transgene
was expressed, and expression was always higher in the liver
than in the other tissues. The transgenic mice containing the
smaller apoVLDL II construct (9V) from which the -16 kb to
-5 kb region was lacking, gave a different tissue pattern of
expression. Examination of total RNA from various tissues
revealed that the tissue-specificity had been lost. Transgene
transcripts were, in addition to liver, detectable in kidney, ovary
plus oviduct, lung, uterus, thymus and heart (Figure 4C, and data
not shown).
Transgenic mice containing construct ViI (carrying the -1 1
kb HSS), gave similar results. On longer exposures, ectopic
expression is found in kidney, uterus (Fig. 4D), thymus (mouse
1 IV15; not shown) and heart (mice 11V5 and 11V6; not shown).
This indicates that the addition of the -11 kb HSS is not sufficient
to restore tissue specificity and we conclude that other upstream
sequences may be required to restrict expression to the liver.
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Figure 4. Tissue distribution of expression in transgenic mice. Five sg total RNA
from various tissues was Northern blotted after gelelectrophoresis, and hybridized
with an apoVLDL II cDNA probe. (A) RNA from transgenic mice 20V20 and
20V17. Lanes 21-23: liver RNA from a hormone-naive rooster, estrogen-treated
rooster and laying hen, respectively. (B) Mice 20V20 and 20V20(-). Lanes
21-23: no RNA, and RNA from mice 20V20 and 20V17, respectively. (C) Mice
9V7 and 9V8. Lanes 21-23; no RNA, 5 tsg and 0.5 Ug liver RNA from mouse
20V17, respectively. (D) Mice llV9 and llV13. Lane 21: liver RNA from a
laying hen. Short (upper) and long (lower) exposures are shown in panel A (3
hr and 7 days), panel C(2 hr and 2 days), panel D (3 hr and 3 days). Panel B
shows a 3-hr exposure. L, liver; 0, ovary and oviduct; Ts, testis; S, spleen;
K, kidney; B, brain; T, thymus; Lu, lung; H, heart; I, small intestine; U, uterus.
DNAsel HSS mapping of the apoVLDL II transgene in mice
In chicken, constitutive DNasel HSS were found at -11 kb and
-1,7 kb and estrogen-inducible HSS at -8 kb and in the
promoter region (17 and unpublished data). These HSS are
present in liver but not in kidney. In the present study, we
examined the HSS in the livers of hormone-treated and hormone-
naive transgenic mice 20V20 containing the larger VLDL
fragment. EcoRl- or BamHI-fragments of DNA from DNaseI-
treated nuclei were Southern blotted and hybridized with probes
abutting suitable restriction sites.
Viewing from the EcoRI site within the transcribed region (see
Fig. 1) upstream into the 5' flanking DNA, we detect
hypersensitive sites at the promoter and at 1.7 kb in front of the
gene (Figure 5A). These sites co-localize with the hypersensitive
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Figure 5. DNAaseI-hypersensitive site mapping at the apoVLDL II gene. Nuclei
were isolated and treated with DNAaseI (see Materials and Methods). DNA was
purified and restricted with EcoRI (A) or BamHI (B) and Southern blotted. Liver
RNA was from nuclei from estrogen treated (+) or from hormone-naive (-)
three-week old male transgenic (20V20) mice and rooster. The wedges indicate
an increasing amount of DNAseI. The DNaseI hypersensitive regions are indicated
by dotted blocks and their map position relative to the apoVLDL II cap site. The
band indicated by a star is DNaseI-independent. Positions and sizes of marker
DNA fragments are indicated to the right of each panel. (A) EcoRI blot hybridized
with probe 2 (Fig. 1), (B) BamHI blot hybridized with probe 4 (Fig. 1).
sites in chicken (17). The hypersensitivity of the -1.7 region
in mice was constitutive as it is in chicken. However, for the
promoter region we observe a notable difference between chicken
and mice. In non-stimulated rooster liver this region did not
contain hypersensitive sites, implying that protein-DNA
interactions at the promoter do not occur prior to hormone
administration, a conclusion which has been directly corroborated
by genomic footprinting (18,19). However, in non-stimulated
transgenic mice hypersensitive sites were found indicating that
interaction of DNA-binding proteins with the promoter can take
place prior to hormone administration. It is possible that the high
gene copy number of transgenic mice has facilitated the detection
of unstable protein-promoter complexes. The presence of very
low levels of apoVLDL II transcripts in non-stimulated transgenic
mice indicates that at least some of these interactions may reach
the stage of productive transcription complexes. However, the
absence of transcripts in rooster, implying that the promoter is
completely closed, indicates that the chromatin conformation in
chicken and transgenic mice may differ more fundamentally for
example in the precise positioning of the nucleosomes.
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Figure 6. ApoVLDL II mRNA levels in transgenic mice. For each transgene
construct, the average apoVLDL mRNA levels relative to the i3-actin mRNA
levels listed in table I are depicted. The number of mice is indicated above the bars.
With another probe specific for the 5' end of the far-upstream
region from - 12,5 kb to -5 kb, we detected one HSS at -10.8
kb in induced as well as non-induced mouse liver (Figure SB).
The [-8 kb] HSS that has been found in chicken is however
absent in the transgenic mice. The same results were obtained
with a probe that labels the 3' end of this far-upstream region
(data not shown). The presence of the -11 kb HSS and the
absence of the - 8 kb HSS in transgenic mice suggest that only
the former site is involved in modulation of the apoVLDL gene
transcription.
The upsteam sequence contains a negative regulating element
at -11 kb
The expression data of three different constructs (20V, I1V and
9V) are depicted in Table I and Figure 6. Within each group
of transgenes generated with a particular construct, the expression
showed no correlation with the gene-copy number. However,
the gross apoVLDL II expression appears to reach a certain level
for each group. The largest construct (20V) gave a 5-fold lower
expression than the shortest construct (9V). This operationally
defines the region extending from -5 to -16 kb 5' flanking to
the gene as a negative regulating DNA fragment. To further
localize the responsible Negative Regulating Element(s) (NREs)
within this fragment, we have investigated the effect of a 2-kb
subfragment, containing the -11 kb HSS, linked to the 9V
construct on the transcription of the apoVLDL II transgene. This
construct, 1IV, showed a 5-fold reduced activity when compared
to the 9V construct. This identifies the fragment covering the
-11 kb hypersensitive sites as a NRE.
DISCUSSION
In this report, we show that the chicken apoVLDL II gene can
be correctly transcribed in transgenic mice and that the expression
is tissue-specific and estrogen-inducible. The expression in liver
was of high-level and varied moderately between mice carrying
the same gene construct, indicating that position effects did not
play a dominant role. Expression did not follow gene copy
number implying that the apoVLDL II fragment tranferred to
the mice did not comprise a locus control region. Sequences far-
upstream of the gene were shown to repress transcription in
tissues where the gene is normally not transcribed. In addition,
these far-upstream sequences contain a negative regulating
element which map at hypersensitive sites at 11 kb in front of
the gene. The correct initiation and poly-adenylation of the
apoVLDL II transcript in the livers of transgenic mice implies
that the cis-acting DNA elements and trans-acting factors are
largely conserved between chicken and mouse. The result is in
agreement with the proper expression in transgenic mice of the
chicken lysozyme (13) and ,3-globin genes (16) in macrophages
and erythropoietic cells, respectively.
Expression of transgenes is often influenced by the regulatory
elements present in the mouse genome near the site of integration.
This results in a highly variable level of transcription which does
not correlate with the gene copy number and often shows a more
or less promiscuous tissue pattern of expression. Tissue-specific,
position-independent, copy-number dependent expression of
transgenes has been obtained with the human (-globin (15) and
CD2 genes (14), and the chicken lysozyme (13) and ,B-globin
genes (16). In these examples, chromosomal position effects are
overruled by Locus Control Regions. ApoVLDL II gene
expression in our transgenic mice did not follow copy number,
but appeared to reach a certain final level for each particular
construct. From this we conclude that the position effects of
mouse sequences at the site of integration are relatively minor.
Our results show that the information for high expression in liver
resides in a 9-kb DNA segment extending from 5 kb 5' flanking
to the transcribed region to 0.4 kb 3' flanking to the gene. A
putative candidate for this specific activity is the constitutive HSS
at - 1.7 kb where we find genomic DMS and DNasel footprints
in liver and oviduct compared with erythrocytes around -1935
and - 1831 (18,19; unpublished data). Other candidates are the
hormone-inducible DNasel HSS at the promoter region and in
the third intron (17).
In this report, it is shown that the far-upstream region contains
a Negative Regulating Element at -11 kb. This situation is
somewhat resembling the situation in the 5' flanking region of
the chicken lysozyme gene, where upstream NRE's downregulate
the expression of the gene (39). The following question arises:
What physiological role may the NRE have? High expression
levels of the gene might, like the human apoCi VLDL gene
in transgenic mice, give rise to a form of hypertriglyceridemia
(8). The apoVLDL gene would need some kind of modulation
to prevent overexpression, and the NRE at -11 kb might be used
to reduce the expression after the removal of the inducing
stimulus.
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